Podcast: LA PrEP Considerations
Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP

Released: March 21, 2022

Expiration: March 20, 2023

Activity

Progress
1
Course Completed

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on:

  • The FDA approval of long-acting cabotegravir for PrEP
  • Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy
  • Considerations for long-acting cabotegravir as PrEP
    • Dosing and administration
    • Managing missed doses
    • Discontinuation
    • Delays in HIV diagnoses found in the HPTN 083 study in men
  • CDC recommendations for HIV screening while receiving PrEP